JP2007505159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505159A5 JP2007505159A5 JP2006533223A JP2006533223A JP2007505159A5 JP 2007505159 A5 JP2007505159 A5 JP 2007505159A5 JP 2006533223 A JP2006533223 A JP 2006533223A JP 2006533223 A JP2006533223 A JP 2006533223A JP 2007505159 A5 JP2007505159 A5 JP 2007505159A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- erythropoietin
- injury
- administered
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 58
- 102000003951 Erythropoietin Human genes 0.000 claims 52
- 108090000394 Erythropoietin Proteins 0.000 claims 52
- 229940105423 erythropoietin Drugs 0.000 claims 52
- 230000006378 damage Effects 0.000 claims 40
- 208000014674 injury Diseases 0.000 claims 36
- 210000004027 cell Anatomy 0.000 claims 33
- 238000000034 method Methods 0.000 claims 30
- 208000027418 Wounds and injury Diseases 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 102000004127 Cytokines Human genes 0.000 claims 22
- 108090000695 Cytokines Proteins 0.000 claims 22
- 230000002669 organ and tissue protective effect Effects 0.000 claims 22
- 230000001225 therapeutic effect Effects 0.000 claims 22
- 210000004962 mammalian cell Anatomy 0.000 claims 14
- 210000000056 organ Anatomy 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 10
- 230000008733 trauma Effects 0.000 claims 9
- 150000001720 carbohydrates Chemical class 0.000 claims 8
- 235000014633 carbohydrates Nutrition 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 108010027485 asialoerythropoietin Proteins 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 230000003325 follicular Effects 0.000 claims 4
- 210000003494 hepatocyte Anatomy 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 210000001013 sinoatrial node Anatomy 0.000 claims 4
- 210000000278 spinal cord Anatomy 0.000 claims 4
- 210000002536 stromal cell Anatomy 0.000 claims 4
- 210000005168 endometrial cell Anatomy 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000035899 viability Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000005400 Synovial Cyst Diseases 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010047139 Vasoconstriction Diseases 0.000 claims 2
- 210000002556 adrenal cortex cell Anatomy 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 210000001992 atrioventricular node Anatomy 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 210000003050 axon Anatomy 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 210000003737 chromaffin cell Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 229960003067 cystine Drugs 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 210000003158 enteroendocrine cell Anatomy 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 230000001434 glomerular Effects 0.000 claims 2
- 210000003904 glomerular cell Anatomy 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 210000002175 goblet cell Anatomy 0.000 claims 2
- 238000005534 hematocrit Methods 0.000 claims 2
- 210000002287 horizontal cell Anatomy 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims 2
- 210000003292 kidney cell Anatomy 0.000 claims 2
- 210000001865 kupffer cell Anatomy 0.000 claims 2
- 210000005265 lung cell Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 2
- 229960001810 meprednisone Drugs 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 210000004457 myocytus nodalis Anatomy 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000003668 pericyte Anatomy 0.000 claims 2
- 210000000608 photoreceptor cell Anatomy 0.000 claims 2
- 230000002947 procoagulating effect Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 208000032253 retinal ischemia Diseases 0.000 claims 2
- 210000001116 retinal neuron Anatomy 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 210000000717 sertoli cell Anatomy 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000025033 vasoconstriction Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47166103P | 2003-05-19 | 2003-05-19 | |
| PCT/US2004/015733 WO2004112693A2 (en) | 2003-05-19 | 2004-05-19 | Tissue protective cytokines with an extended therapeutic window |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505159A JP2007505159A (ja) | 2007-03-08 |
| JP2007505159A5 true JP2007505159A5 (2) | 2007-07-05 |
Family
ID=33539032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533223A Withdrawn JP2007505159A (ja) | 2003-05-19 | 2004-05-19 | 延長された治療ウインドウを有する、応答性細胞、組織および器官の保護、回復および増強のための組織保護サイトカイン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090258821A1 (2) |
| EP (1) | EP1633305A2 (2) |
| JP (1) | JP2007505159A (2) |
| KR (1) | KR20060013547A (2) |
| CN (1) | CN1946416A (2) |
| BR (1) | BRPI0410470A (2) |
| CA (1) | CA2526096A1 (2) |
| EA (1) | EA200501828A1 (2) |
| IL (1) | IL172035A0 (2) |
| IS (1) | IS8156A (2) |
| MX (1) | MXPA05012515A (2) |
| NO (1) | NO20056000L (2) |
| WO (1) | WO2004112693A2 (2) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| NZ542092A (en) * | 2003-03-27 | 2008-04-30 | Janssen Pharmaceutica Nv | Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| US20080305990A1 (en) * | 2004-07-02 | 2008-12-11 | The Kenneth S Warren Institute, Inc. | Method of Producing Fully Carbamylated Erythropoietin |
| DE602005014117D1 (de) * | 2004-07-07 | 2009-06-04 | Lundbeck As Valby H | Neues carbamyliertes epo und verfahren zu dessen herstellung |
| US8653028B2 (en) | 2005-04-29 | 2014-02-18 | Rui Rong Yuan | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| US9585932B2 (en) | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
| TW201129374A (en) * | 2009-10-26 | 2011-09-01 | Lundbeck & Co As H | Use of carbamylated erythropoietin for the treatment of Friedreich's ataxia |
| US9956265B2 (en) * | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
| ES2912042T3 (es) * | 2011-06-24 | 2022-05-24 | Nono Inc | Terapia de combinación para isquemia |
| US9241970B2 (en) | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
| US10695402B2 (en) * | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
| RU2762892C1 (ru) * | 2021-02-18 | 2021-12-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ коррекции микроциркуляторных нарушений сетчатки асиалированным эритропоэтином |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| NZ542092A (en) * | 2003-03-27 | 2008-04-30 | Janssen Pharmaceutica Nv | Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime |
-
2004
- 2004-05-19 BR BRPI0410470-6A patent/BRPI0410470A/pt not_active IP Right Cessation
- 2004-05-19 WO PCT/US2004/015733 patent/WO2004112693A2/en not_active Ceased
- 2004-05-19 MX MXPA05012515A patent/MXPA05012515A/es not_active Application Discontinuation
- 2004-05-19 CA CA002526096A patent/CA2526096A1/en not_active Abandoned
- 2004-05-19 EP EP04752708A patent/EP1633305A2/en not_active Withdrawn
- 2004-05-19 CN CNA2004800208589A patent/CN1946416A/zh active Pending
- 2004-05-19 JP JP2006533223A patent/JP2007505159A/ja not_active Withdrawn
- 2004-05-19 KR KR1020057022113A patent/KR20060013547A/ko not_active Withdrawn
- 2004-05-19 EA EA200501828A patent/EA200501828A1/ru unknown
-
2005
- 2005-11-17 IL IL172035A patent/IL172035A0/en unknown
- 2005-11-18 US US11/283,024 patent/US20090258821A1/en not_active Abandoned
- 2005-11-29 IS IS8156A patent/IS8156A/is unknown
- 2005-12-16 NO NO20056000A patent/NO20056000L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505159A5 (2) | ||
| ES2332057T3 (es) | Muteinas del factor de crecimiento de fibroblastos 21. | |
| CN101588820A (zh) | α-乳清蛋白组合物 | |
| CN101361961B (zh) | 多肽小分子在制备防治缺血性脑血管病药物中的应用 | |
| US20240368235A1 (en) | Disease Treatment Drug Based on Mesenchymal-Stem-Cell Mobilization | |
| US20250115939A1 (en) | Neural Repair Protein Composition and Preparation Method thereof and Use thereof | |
| JP2009508471A5 (2) | ||
| JP5699157B2 (ja) | 長期熟成在来式醤油から分離したメイラードペプチドを有効成分として含むｔｒｐｖ１活性関連疾患または炎症関連疾患の予防または治療のための薬学的組成物 | |
| TW200843794A (en) | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles | |
| Whitson et al. | Muscle multiorgan crosstalk with MG53 as a myokine for tissue repair and regeneration | |
| WO2001015717A1 (en) | Brain cell or nerve cell protecting agents comprising ginseng | |
| JP2019527053A (ja) | 可溶性線維芽細胞成長因子受容体３（ｓＦＧＦＲ３）ポリペプチドおよびその使用 | |
| CN110041408A (zh) | 一种小分子多肽及其在制备防治帕金森综合症药物中的应用 | |
| DE60207043T2 (de) | Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese | |
| US9580490B2 (en) | Uses of modified human tumor necrosis factor receptor-1 polypeptide | |
| Wang et al. | Platelet microvesicles promote the recovery of neurological function in mouse model of cerebral infarction by inducing angiogenesis | |
| EA007812B1 (ru) | Эритропоэтины длительного действия, которые сохраняют тканезащитную активность эндогенного эритропоэтина | |
| KR102414649B1 (ko) | 에리스로포이에틴-유래된 펩타이드, 이의 제조 방법 및 이의 용도 | |
| Im et al. | Comparison of insulin receptors from bovine retinal blood vessels and nonvascular retinal tissue. | |
| JP2013523719A (ja) | 血管新生促進用ペプチド及びその使用 | |
| JP7016125B2 (ja) | 脳梗塞の治療薬 | |
| CN101503458B (zh) | 预防和治疗血管新生的小分子多肽及其应用 | |
| EP3967706A1 (en) | Aav mutant that efficiently infects supporting cells | |
| CN115944713A (zh) | 一种神经营养因子和穿透肽组合物及其应用 | |
| JP2026505888A (ja) | Ｄｒ５ドメインバリアント及びその応用 |